{
    "organizations": [],
    "uuid": "cd70549269f653eaec977aab7f80bfa9e46dd8be",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vifor-pharma-ferroportin-inhibitor/brief-vifor-pharma-ferroportin-inhibitor-enters-phase-i-clinical-trial-idUSFWN1PY03K",
    "ord_in_thread": 0,
    "title": "BRIEF-Vifor Pharma: Ferroportin Inhibitor Enters Phase-I Clinical Trial ‍​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - VIFOR PHARMA AG:\n* FERROPORTIN INHIBITOR ENTERS PHASE-I CLINICAL TRIAL ‍​ * FIRST RESULTS FROM THE STUDY ARE EXPECTED IN THE SECOND HALF OF 2018‍​ Source text - bit.ly/2FSyjCD Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-08T14:11:00.000+02:00",
    "crawled": "2018-02-09T16:47:12.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "vifor",
        "pharma",
        "ag",
        "ferroportin",
        "inhibitor",
        "enters",
        "clinical",
        "trial",
        "first",
        "result",
        "study",
        "expected",
        "second",
        "half",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}